menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Exploring Biomarker Testing in NSCLC: Current Guidelines & Testing Considerations

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Hear Dr. Ticiana Leal discuss the importance of biomarkers, testing patterns, and potential ways to improve biomarker testing rates in patients with non-small cell lung cancer (NSCLC).

  • Sponsored by

  • Overview

    The biomarker landscape has evolved in recent years with an increasing number of actionable biomarkers and targeted therapies for patients with NSCLC.1

    With nearly 40% of patients with non-squamous NSCLC having an actionable molecular biomarker, guideline-recommended biomarker testing results may help patients with advanced NSCLC.2,3

    Join Dr. Ticiana Leal, a medical oncologist and Director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine, as she discusses the importance of biomarker testing when managing patients with NSCLC.

    1. Cheng Y, et al. MedComm. 2021;2:692-729. 
    2. Data on file, Amgen; 2020.
    3. John A, et al. Adv Ther. 2021;38:1552-1566.

    ©2022 Amgen Inc. All rights reserved. USA-510-80955 03/22

Schedule28 May 2022
Webpack App